Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | GALR3 | O60755 | 2/20 | 0.53 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6446137 | 0.84 | LMNA (0.69) | LMNAPKMTNFHTTTP53 | |
| SCHEMBL25710995 | 0.83 | TNF (0.58) | LMNAPKMTNFHTTTP53 | |
| SCHEMBL24943126 | 0.81 | LMNA (0.64) | LMNAHTTTP53KDM4EMEN1 | |
| SCHEMBL18997334 | 0.80 | LMNA (0.62) | LMNAHTTTP53KDM4EMEN1 | |
| SCHEMBL229041 | 0.80 | POLB (0.67) | LMNAPKMTNFHTTTP53 | |
| SCHEMBL2330274 | 0.80 | LMNA (0.69) | LMNAPKMTNFHTTTP53 | |
| SCHEMBL13587989 | 0.79 | LMNA (0.51) | LMNAPKMTNFHTTTP53 | |
| SCHEMBL8364740 | 0.78 | LMNA (0.64) | LMNATNFHTTTP53KDM4E | |
| SCHEMBL8365517 | 0.78 | LMNA (0.68) | LMNAHTTTP53KDM4EMEN1 | |
| SCHEMBL760728 | 0.78 | PKM (0.60) | LMNAPKMTNFHTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | LMNA 3109/4885PKM 4532/4885TNF 1633/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | LMNA 3109/4885PKM 4532/4885TNF 1633/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | LMNA 3509/4885PKM 1484/4885TNF 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.